PT1471902E - Métodos para o tratamento da perda de audição - Google Patents

Métodos para o tratamento da perda de audição Download PDF

Info

Publication number
PT1471902E
PT1471902E PT3701231T PT03701231T PT1471902E PT 1471902 E PT1471902 E PT 1471902E PT 3701231 T PT3701231 T PT 3701231T PT 03701231 T PT03701231 T PT 03701231T PT 1471902 E PT1471902 E PT 1471902E
Authority
PT
Portugal
Prior art keywords
compositions
methods
hearing loss
treating hearing
treating
Prior art date
Application number
PT3701231T
Other languages
English (en)
Inventor
Jonathan Kil
Eric D Lynch
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of PT1471902E publication Critical patent/PT1471902E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
PT3701231T 2002-01-04 2003-01-03 Métodos para o tratamento da perda de audição PT1471902E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34581302P 2002-01-04 2002-01-04

Publications (1)

Publication Number Publication Date
PT1471902E true PT1471902E (pt) 2014-09-09

Family

ID=23356596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT3701231T PT1471902E (pt) 2002-01-04 2003-01-03 Métodos para o tratamento da perda de audição

Country Status (12)

Country Link
US (2) US6815434B2 (pt)
EP (1) EP1471902B1 (pt)
JP (1) JP4414229B2 (pt)
KR (1) KR20040078663A (pt)
CN (1) CN1635882B (pt)
AU (1) AU2003202219B2 (pt)
CA (2) CA2472678C (pt)
DK (1) DK1471902T3 (pt)
ES (1) ES2497716T3 (pt)
HK (1) HK1072360A1 (pt)
PT (1) PT1471902E (pt)
WO (1) WO2003057207A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352982B2 (en) * 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
AU2003202219B2 (en) * 2002-01-04 2008-10-23 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
EP1645276A1 (en) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Treatment of neurodegenerative disorders
CN1303898C (zh) * 2004-12-29 2007-03-14 李浙烽 复合预混料
WO2006096759A2 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
US20070123555A1 (en) * 2005-09-30 2007-05-31 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US20090155390A1 (en) * 2006-01-19 2009-06-18 Miller Josef M Composition and method of treating temporary and permanent hearing loss
US7951845B2 (en) * 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
EP2535044B1 (en) 2006-01-27 2019-12-18 The Regents of The University of California Enterically coated cysteamine bitartrate and cystamine
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
DK2214480T3 (da) 2007-11-30 2013-07-08 Univ California Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2016033615A1 (en) 2014-08-29 2016-03-03 Sound Pharmaceuticals Incorporated Methods of screening for drugs to prevent noise-induced hearing loss
KR101893604B1 (ko) * 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CN109475518A (zh) * 2016-05-18 2019-03-15 桑得医药品公司 梅尼埃病的治疗
CN114848836B (zh) * 2021-07-06 2023-09-15 中山大学孙逸仙纪念医院 一种偶联物及其在治疗内耳疾病上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE3670635D1 (de) * 1985-04-27 1990-05-31 Nattermann A & Cie Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3638124C2 (de) 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
DE4024885C2 (de) 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE19856210A1 (de) * 1998-10-26 2000-04-27 Albert Lind Verwendung von Thiolverbindungen, Oxidoreduktasen und/oder Hydrolasen zur Behandlung des Tinnitus, insbesondere des chronischen Tinnitus
WO2001080832A2 (en) 2000-04-26 2001-11-01 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
AU2002352982B2 (en) * 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
AU2003202219B2 (en) * 2002-01-04 2008-10-23 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
US7208514B2 (en) 2003-03-13 2007-04-24 Mitsubishi Pharma Corporation Tumorigenesis inhibitor
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors

Also Published As

Publication number Publication date
CN1635882A (zh) 2005-07-06
EP1471902A4 (en) 2007-05-23
CA2825792C (en) 2016-08-16
CN1635882B (zh) 2010-11-10
US6815434B2 (en) 2004-11-09
CA2472678A1 (en) 2003-07-17
CA2825792A1 (en) 2003-07-17
EP1471902B1 (en) 2014-07-02
DK1471902T3 (da) 2014-09-08
AU2003202219A1 (en) 2003-07-24
ES2497716T3 (es) 2014-09-23
AU2003202219B2 (en) 2008-10-23
JP4414229B2 (ja) 2010-02-10
CA2472678C (en) 2013-12-03
US7820640B2 (en) 2010-10-26
JP2005516028A (ja) 2005-06-02
US20030162747A1 (en) 2003-08-28
WO2003057207A1 (en) 2003-07-17
HK1072360A1 (en) 2005-08-26
US20040220145A1 (en) 2004-11-04
KR20040078663A (ko) 2004-09-10
EP1471902A1 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
HK1072360A1 (en) Compositions for use in methods for treating hearing loss
AP2089A (en) Compositions and methods for combination antiviraltherapy
HK1089676A1 (en) Formulations and methods for treating rhinosinusitis
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
AU2003284242A8 (en) Methods and compositions for use in treating cancer
IL176259A0 (en) Compositions and methods for treating diabetes
GB0411940D0 (en) Methods and compositions
IL164000A0 (en) Compositions and methods for treating emphysema
EP1701725A4 (en) PROCESS AND COMPOSITIONS
EP1680535A4 (en) METHODS AND COMPOSITIONS FOR GALVANOPLASTY
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
GB0428214D0 (en) Polishing composition and polishing method
AU2003297573A8 (en) Compositions and methods for treating transplants
EP1684771A4 (en) COMPOSITION AND METHOD
GB0428054D0 (en) Polishing composition and polishing method
EP1626711A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2003238905A1 (en) Surface treating compositions and methods for using same
EP1593459A4 (en) GRINDING PROCESS
AU2003275433A8 (en) Compositions and methods for treating pain
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003275240A8 (en) Methods and compositions for soluble cpg15
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
EP1369108A4 (en) COMPOSITION FOR USE IN ELECTROPORATION